The STOP-MED CTRCD Trial for Heart Failure after Cancer Treatment

This study is for adults who had cancer treatment (like anthracyclines or HER2-targeted therapy) more than six months ago and developed heart problems called cancer therapy-related cardiac dysfunction (CTRCD). This means your heart's ability to pump blood was affected. If your heart function has since returned to normal with heart failure medications, this study wants to see if you can safely stop those medications under medical supervision. The study will measure if your CTRCD relapses (comes back) one year after stopping the medications. We plan to enroll 335 participants.

Study design: This is an interventional study with 335 planned participants. It is testing if stopping heart failure medications is safe for certain cancer survivors.
What's involved: You would stop your heart failure medication(s) under the supervision of the study team. The primary endpoint is measured at 1 year.
Compensation: Not stated in the trial record.
Follow-up: Your heart function will be monitored for relapse of cancer therapy-related cardiac dysfunction for at least 1 year after stopping medication.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

The STOP-MED CTRCD Trial

Recruiting

PHASE4Ages 18+InterventionalTreatment

Dinesh Thavendiranathan

~335 participants

Updated 2026-07-07 on ClinicalTrials.gov

What's tested:Stopping Heart Failure Medication(s)

At a glance

Recruiting sites

8 of 14 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Cancer Therapy Related Cardiac Dysfunction Relapse

Measured over 1 year

Conditions

Heart Failure

Cardiotoxicity

Cardiac Toxicity

Antineoplastics Toxicity

Cancer

Where it's being run

14 sites across 10 states

Ontario4

United Kingdom2

California1

Massachusetts1

Victoria1

Alberta1

Manitoba1

Poland1

Who to contact

Paaladinesh Thavendiranathan, MD

[email protected]

416-340-5326

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Adult patients (age ≥18 years) with cancer therapy completed more than 6 months prior (other than hormonal therapy) and no plan for further cancer treatments with potential risk for CTRCD.

Prior cancer therapy with anthracyclines and/ or HER2-targeted therapy.

Prior asymptomatic, moderate to severe CTRCD, defined using the ESC/ICOS criteria (MODERATE: ≥10% drop in LVEF from baseline to 40% to 49.9% OR \<10% drop to 40-49.9% with a reduction in GLS by \>15% or new abnormal Troponin I/T or NT-proBNP or SEVERE: new LVEF reduction to \<40% from normal baseline LVEF), diagnosed within 1 year of completing potentially cardiotoxic cancer therapy.

Current use of ≥1 HF medication started for CTRCD for at least 6 months with LVEF ≥50% by recently performed (≤6 months) echocardiogram, normal sex and age adjusted NT-proBNP or BNP ≤97.5th Centile, and no symptoms attributable to HF.

Reference ranges for NT-proBNP and BNP by age and sex:

Confirmation of LVEF ≥50% and normal volumes at baseline CMR (i.e., some patients recruited based on echocardiography, may be excluded if baseline CMR LVEF/volumes are not normal). This is included given that the primary outcome includes the use of CMR LVEF.

Normal Ventricular end-diastolic volumes by CMR as defined by the Society of Cardiac Magnetic Resonance 2025 update.

Exclusion

Indication for continuation of HF medications i.e., ongoing HF symptoms, chronic kidney disease (CKD), vascular disease, atrial or ventricular arrythmias, other (note: participants with hypertension pre-CTRCD will continue their antihypertensive as only medication started for CTRCD will be ceased).

Contraindications for CMR (e.g., MRI non-compatible implanted pacemakers).

Patients with cardiac devices i.e. defibrillator, CRT, pacemaker, etc.

Continued use of loop diuretic therapy for heart failure purposes i.e., furosemide.

Life expectancy \<1 year or metastatic disease.

Prior history of major cardiovascular event (defined as myocardial infarction, cerebral vascular event, admission for HF) or therapeutic cardiovascular procedure (e.g., percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG)).

Issues that prevent communication, understanding or presentation for study-related visits and inability to provide informed consent.

What this trial measures

Cancer Therapy Related Cardiac Dysfunction Relapse1 year
To compare the proportion of those that develop by 1 year of follow-up one or both of the following (i) left ventricular ejection fraction \<50% and an absolute decline of \>5% from baseline by cardiac magnetic resonance (CMR) (ii) new heart failure signs (at least two physical findings or one physical finding and one laboratory finding) AND symptoms (at least one) with the initiation of qualifying heart failure therapy.

Trialytics